KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2026)

Aquestive Therapeutics has reported Operating Expenses over the past 9 years, most recently at $41.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 64.48% year-over-year to $41.9 million; the TTM value through Dec 2025 reached $115.6 million, up 30.87%, while the annual FY2025 figure was $115.6 million, 30.87% up from the prior year.
  • Operating Expenses for Q4 2025 was $41.9 million at Aquestive Therapeutics, up from $24.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $41.9 million in Q4 2025 and troughed at $15.4 million in Q3 2023.
  • A 5-year average of $22.2 million and a median of $21.4 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: crashed 32.95% in 2023 and later soared 64.48% in 2025.
  • Year by year, Operating Expenses stood at $22.7 million in 2021, then decreased by 5.94% to $21.4 million in 2022, then dropped by 20.0% to $17.1 million in 2023, then skyrocketed by 48.66% to $25.4 million in 2024, then soared by 64.48% to $41.9 million in 2025.
  • Business Quant data shows Operating Expenses for AQST at $41.9 million in Q4 2025, $24.3 million in Q3 2025, and $21.4 million in Q2 2025.